{"links":{"html":"https://www.erudio.com/reports/cupisco-nct03498521","json":"https://www.erudio.com/reports/cupisco-nct03498521.json","markdown":"https://www.erudio.com/reports/cupisco-nct03498521.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"cupisco-03498521"}},"request":"https://www.erudio.com/contact?report=cupisco-03498521"},"offer":{"cited_commentary_sources":62,"verified_hcp_statements":358,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":20,"optional":true,"price_per_verified_person_usd":15,"price_usd":300,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"cupisco-nct03498521"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=cupisco-03498521","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/cupisco-nct03498521","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T13:43:34.189306Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":1},"aspects":[{"claim_count":28,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":20,"title":"Primary endpoint: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)"},{"claim_count":16,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":13,"title":"Secondary endpoint: Overall Survival (OS)"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":2,"title":"Secondary endpoint: Objective Response Rate (ORR)"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":2,"title":"Secondary endpoint: Duration of Response (DOR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":0,"title":"Secondary endpoint: Disease Control Rate (DCR)"},{"claim_count":31,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":13,"title":"Population and setting"},{"claim_count":33,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":15,"title":"The comparison"},{"claim_count":3,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.interventions","source_count":3,"title":"Safety and tolerability"},{"claim_count":35,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":17,"title":"Design and conduct"},{"claim_count":23,"coverage":"discussed","id":"A1","source_count":10,"title":"Timing of profiling and limits of the primary-tumor search"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":11,"title":"Origin inference, alternative treatment selection and diagnostic harm"},{"claim_count":9,"coverage":"discussed","id":"A3","source_count":3,"title":"Tissue stewardship and liquid-biopsy feasibility"},{"claim_count":21,"coverage":"discussed","id":"A4","source_count":13,"title":"Treatment access, guideline adoption and referral"},{"claim_count":33,"coverage":"discussed","id":"A5","source_count":23,"title":"Patient experience, durable-remission anecdotes and noncurative expectations"},{"claim_count":30,"coverage":"discussed","id":"A6","source_count":11,"title":"Molecular heterogeneity, proposed classification and next research priorities"},{"claim_count":31,"coverage":"discussed","id":"A7","source_count":8,"title":"Integrated-care value, benefit magnitude and resource allocation"}],"counts":{"cited_sources":68,"claims_by_expression_type":{"comparison":22,"experience":24,"interpretation":90,"opinion":96,"primary_context":35,"question":10,"restatement":45,"uncertainty":14,"unspecified":22},"claims_by_kind":{"objective_result":4,"protocol_statement":20,"publication_statement":86,"source_observation":248},"clinician_statements":37,"evidence_units":265,"findings":12,"organisational_accounts":10,"people_cited":29,"people_identity_verified":20,"people_total":32,"screened_sources":116,"verified_claims":358},"findings_index":[{"id":"F1","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":5,"views":10},"has_counterview":true,"limitations":2,"links":{"context":1,"support":19},"ma_question":true,"named_voices":5,"passages":15,"sources":10,"sources_by_kind":{"commentary":5,"media":4,"publication":1}},"title":"A positive PFS result is not an established overall-survival benefit"},{"id":"F2","structure":{"claims":30,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":5,"views":21},"has_counterview":true,"limitations":2,"links":{"context":0,"support":31},"ma_question":true,"named_voices":6,"passages":27,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Clinical magnitude and integrated-care value are different arguments"},{"id":"F3","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":2,"views":5},"has_counterview":true,"limitations":4,"links":{"context":0,"support":14},"ma_question":true,"named_voices":4,"passages":13,"sources":7,"sources_by_kind":{"commentary":3,"media":3,"publication":1}},"title":"The strategy result does not prove every treatment stratum or the atezolizumab add-on"},{"id":"F4","structure":{"claims":29,"claims_by_group":{"comparisons":1,"experience":2,"questions":1,"restated":16,"views":9},"has_counterview":true,"limitations":2,"links":{"context":0,"support":31},"ma_question":true,"named_voices":5,"passages":29,"sources":11,"sources_by_kind":{"commentary":1,"media":7,"publication":2,"registry":1}},"title":"Population selection determines comparator validity and the place of local treatment"},{"id":"F5","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":4,"passages":11,"sources":7,"sources_by_kind":{"commentary":1,"media":5,"registry":1}},"title":"Early profiling is advocated alongside, not instead of, a sufficient diagnostic work-up"},{"id":"F6","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":1,"questions":3,"restated":3,"views":8},"has_counterview":true,"limitations":2,"links":{"context":1,"support":19},"ma_question":true,"named_voices":11,"passages":18,"sources":11,"sources_by_kind":{"commentary":7,"media":4}},"title":"Tissue-of-origin treatment remains an explicitly contested alternative"},{"id":"F7","structure":{"claims":28,"claims_by_group":{"comparisons":4,"experience":3,"questions":2,"restated":7,"views":12},"has_counterview":true,"limitations":2,"links":{"context":0,"support":32},"ma_question":true,"named_voices":6,"passages":24,"sources":12,"sources_by_kind":{"commentary":5,"media":4,"publication":3}},"title":"Diagnostic rigor is viewed as both a major strength and a barrier to participation"},{"id":"F8","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":5,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":1,"passages":7,"sources":4,"sources_by_kind":{"media":3,"registry":1}},"title":"Liquid biopsy addresses a real tissue constraint, with qualified feasibility and access"},{"id":"F9","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":1,"views":10},"has_counterview":true,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":6,"passages":9,"sources":9,"sources_by_kind":{"commentary":4,"media":5}},"title":"Testing, treatment access and referral must be considered together"},{"id":"F10","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":5},"has_counterview":false,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":5,"sources":5,"sources_by_kind":{"commentary":1,"media":2,"publication":2}},"title":"Favorable tolerability language does not mean no harm or no monitoring burden"},{"id":"F11","structure":{"claims":38,"claims_by_group":{"comparisons":0,"experience":4,"questions":4,"restated":7,"views":23},"has_counterview":true,"limitations":2,"links":{"context":3,"support":39},"ma_question":true,"named_voices":20,"passages":37,"sources":25,"sources_by_kind":{"commentary":19,"media":6}},"title":"Patient experience gives the findings meaning without establishing cure"},{"id":"F12","structure":{"claims":39,"claims_by_group":{"comparisons":3,"experience":1,"questions":4,"restated":9,"views":22},"has_counterview":true,"limitations":3,"links":{"context":4,"support":44},"ma_question":true,"named_voices":6,"passages":36,"sources":14,"sources_by_kind":{"commentary":6,"media":5,"publication":3}},"title":"Molecularly informed classification is proposed, with integrated assessment and treatment-specific validation still needed"}],"medical_affairs_question":"How should Medical Affairs communicate the value of early molecularly informed care while making endpoint uncertainty, treatment-specific evidence limits and feasible access explicit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Keep PFS, OS and unspecified survival language separate"},{"id":"section-2","level":2,"title":"2. Distinguish a modest aggregate gain from a claim of systems-level importance"},{"id":"section-3","level":2,"title":"3. Separate pooled strategy evidence, actionable-target observations and the atezolizumab question"},{"id":"section-4","level":2,"title":"4. Resolve applicability before debating comparators or local treatment"},{"id":"section-5","level":2,"title":"5. Preserve the conditions behind early testing and stopping the primary search"},{"id":"section-6","level":2,"title":"6. Keep origin inference and actionable-alteration selection distinct"},{"id":"section-7","level":2,"title":"7. Diagnostic rigor enables interpretable evidence but limits who reaches randomization"},{"id":"section-8","level":2,"title":"8. Tissue scarcity makes alternative sampling clinically consequential"},{"id":"section-9","level":2,"title":"9. Access depends on the whole pathway and on local circumstances"},{"id":"section-10","level":2,"title":"10. Pair favorable safety and quality-of-life accounts with exposure and monitoring qualifications"},{"id":"section-11","level":2,"title":"11. Preserve patient hope, selected durable benefit and explicit noncurative limits"},{"id":"section-12","level":2,"title":"12. Molecular reclassification is a direction of travel, not one validated universal algorithm"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":2}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F2","shared_claims":1},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":4},{"id":"F12","shared_claims":1}],"id":"T2","label":"Secondary endpoint: Overall Survival (OS)"},{"findings":[],"id":"T3","label":"Secondary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F11","shared_claims":3}],"id":"T4","label":"Secondary endpoint: Duration of Response (DOR)"},{"findings":[],"id":"T5","label":"Secondary endpoint: Disease Control Rate (DCR)"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":21},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F11","shared_claims":3},{"id":"F12","shared_claims":1}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":2},{"id":"F12","shared_claims":4}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F10","shared_claims":3}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":15},{"id":"F11","shared_claims":1},{"id":"F12","shared_claims":3}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T13:43:34.189306Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T13:56:28Z","record_hash":"b2891b3f63b06addefac0bb0d7992ce5dad87f200b13c238f3fc8bd6211932cb","release_hash":"50e8ebef0bdc27df9343580e21a5978ee70a473bf2ab71b4e86717d6896836c2","report_id":"erudio-nct03498521","run_id":"8bebdb48-b396-4550-9fde-2fbe4ff9bf14","schema_version":"5.0","slug":"cupisco-03498521","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on CUPISCO in the sources reviewed for this edition leads to one open question: How should Medical Affairs communicate the value of early molecularly informed care while making endpoint uncertainty, treatment-specific evidence limits and feasible access explicit? Its leading findings: (1) A positive PFS result is not an established overall-survival benefit. (2) clinical magnitude and integrated-care value are different arguments. (3) the strategy result does not prove every treatment stratum or the atezolizumab add-on. 9 more findings follow. 116 sources screened, 68 cited; not all HCPs or all public discussion.","meta_description":"116 sources screened · 358 verified statements (37 from clinicians verified by NPI or staff page) from 68 sources · 12 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-31T13:56:28Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":116},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about treatment selection for cancer of unknown primary.","Not yet captured in this edition: a view on genomic profiling–guided treatment versus platinum chemotherapy in cancer of unknown primary.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","92 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of all HCP opinion. Reposts, shared presentation accounts and repeated statements do not establish independent agreement.","Coverage of connected alternative-study discussions remains incomplete in this edition, including CUP-ONE's diagnostic comparison, separate molecular-strategy studies' survival and reclassification findings, and further research uses of GEFCAPI04 data and tissue. Those questions should not be treated as resolved by this report.","Several podcast and video passages cannot be assigned to a named speaker. Their views remain attributed to the episode or discussion and are not treated as additional distinct clinicians.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Sources describe some contributors as involved in, presenting or reporting CUPISCO. Those descriptions are attributed source context, not independently established trial roles or evidence of external confirmation.","The material spans recruitment-period expectations, initial-results reactions and updated analyses. Post dates do not establish presentation dates, and differences across sources do not establish that a speaker changed their mind.","Some oral accounts use unspecified survival terminology or numbers that differ from publications. They are preserved as statements made rather than silently converted into corrected trial results.","Long remissions, individual survival experiences, retrospective treatment matching and exploratory molecular clusters do not establish comparative efficacy for an individual drug or patient.","Access and reimbursement accounts are local, dated and sometimes explicitly experiential or unverified. A comprehensive current regulatory assessment was not available."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":2,"publication":5,"registry":1,"regulatory":0,"x_thread":46,"x_video":0,"youtube":12},"by_evidence_role":{"commentary":62,"context":2,"methods":1,"results":3},"count":68,"evidence_window":{"end":"2026-09-18","start":"2018-10-19"},"retrieval_snapshot":"2026-10-31T12:42:14.113653Z","timeline":[{"count":1,"week":"2018-W42"},{"count":1,"week":"2019-W23"},{"count":2,"week":"2019-W41"},{"count":1,"week":"2019-W45"},{"count":1,"week":"2019-W49"},{"count":1,"week":"2020-W34"},{"count":1,"week":"2021-W38"},{"count":2,"week":"2022-W36"},{"count":1,"week":"2023-W04"},{"count":1,"week":"2023-W30"},{"count":8,"week":"2023-W42"},{"count":7,"week":"2023-W43"},{"count":3,"week":"2023-W44"},{"count":2,"week":"2023-W45"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W24"},{"count":3,"week":"2024-W31"},{"count":7,"week":"2024-W32"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W15"},{"count":5,"week":"2026-W37"},{"count":1,"week":"2026-W38"}],"undated_sources":7},"quote_policies":[{"id":"clinicaltrials:NCT03498521:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03498521:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03498521:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03498521:sap:1","quote_policy":"short_quote_link_out"},{"id":"pubmed:33219618","quote_policy":"no_derivatives"},{"id":"pubmed:33687747","quote_policy":"no_derivatives"},{"id":"pubmed:37922692","quote_policy":"no_derivatives"},{"id":"pubmed:39096924","quote_policy":"short_quote_link_out"},{"id":"pubmed:42691436","quote_policy":"no_derivatives"},{"id":"openfda:42c49deb-713b-427a-9670-08af08adcffb:20260821","quote_policy":"short_quote_link_out"},{"id":"openfda:eb368bb6-80e3-4df9-8a85-91df0a2ada6a:20241202","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-re36oj25gzkdkmnzioekxnzl-3lbtit7cjvk2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-x2dyjubpnfswhixeznm42xes-3lbrsdyjkjc2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3lboz7g2mxt2f","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7227547494195314690","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:71e320","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:87f968","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1053274968614715392:deaf3d25-489c-4733-986a-273342275df8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1090981544666255360:bfb9be5a-8a0a-4f51-9abc-6dbdeb37701f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1137689126189375488:46a4d35d-1b61-4ac5-96cf-ede85ce5ec61","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1144860642173685762:43d9f416-be6f-4d4d-9af5-3857779dbabc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1177894511969734657:29b4585c-78d1-4270-b560-3b673d59af2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1201813646650888192:e0a99a89-896b-4640-9205-06a0d1b6fb0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1202341749336752137:70c19c50-52a1-4ea6-ad51-afd2c602cde4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1208484810404093955:99cf8169-1eac-4392-b622-d3619fedf39d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1297264047209893888:f22be4d7-bfe0-4c05-9da5-855fde3a9bc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1432123450223648769:b3e643fe-02ad-4d1f-8fd3-d7c7eb7909f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1433559640504033287:de0c839b-d6cd-4b52-bea3-4eb4201601b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1440733357957005321:ba2f71a9-9836-4efb-a8d8-5b4673864d76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1440921411770540032:5264fd0e-2976-4f9a-a151-944920e393dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1511103197791797253:ce949bbe-1b3f-4950-9304-be94a6dcb383","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1517480471541780481:74fe1736-8e13-48f3-9f65-5322a8e95a1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1523136160595333120:4dd6a65c-a94e-4953-8ce8-c4c152b3b999","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1567894816238755841:2d1c9680-49e2-4081-80cf-776e7ec72db3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568562746202914818:aaf8292e-38cf-4dc5-887b-d9277ce10e9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1595779319749832706:f445711a-0df0-4a30-b55f-49b96a8b1268","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1617385600406937606:ab4db759-9213-49dc-a9c8-b9651330615e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640398676970422274:ba0e85e7-58c9-4d01-9c9b-afce4d2ad414","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640406185462448137:a39a7c07-db2a-4ea3-8910-1bde55da2267","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1659967657603481601:e065c4ec-9ba1-480a-9c65-8dfa285647de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1714933856984277377:a95f3b3b-8a06-4dfd-9b5d-c9a2d71c99cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715324348385370326:c1a96755-6f53-4dd7-ac04-8a6bf9343c45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715586701958025227:ec696058-8445-47f2-9e6b-42cbb05132e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715597440919666993:0da6fa44-acae-4963-9e94-2ab57520e75b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715644273498976357:1fda2347-e7ab-40d9-89c9-f1125f03ab12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715647807611097127:39e7c480-3f42-4cea-9312-d710f8b5d045","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715649815223074873:c6bbeda5-0559-4fa4-bf23-225c53dc0a6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715650658018226308:0ad4a9ee-25ee-4a6d-950e-c9c43a9f4c95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715655987292418522:b1eba16e-9b91-43d9-8442-5d074d9fb48c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715670790547308705:5a8b8d2a-aad3-4223-958c-c91bc06ea3b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715706712265482613:2e39e75b-a3d3-4d0c-a61a-b6c0c9caffdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715755168136900861:0676b932-a6f1-4a52-b534-6f8fe18edb17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715767163661750306:64e72c0c-b2eb-4069-a167-04eeab4183ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715963640539484525:4090e089-703b-4629-97a8-08baa79c8ee9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716332400785977782:0288b1be-9cf9-4676-a87b-3482000ac5a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716441863782031476:311e4884-6427-42ec-84ce-c464478a4712","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716936088034652421:ec269f71-fbcb-4c44-a5ce-d83994d05cd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717414078707044739:d96f9605-a662-48a0-b964-a239bb4bfc70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717414136676487288:ad75ca8b-896f-4e7f-9002-9489c915ee13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717414321473343556:8d94fd01-54d5-4124-8c81-0b517d39ae9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717689746930245815:eca320cb-2cb6-407a-af99-d367db058727","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1719330103606612125:f2dd5b4f-b81e-4e50-9747-6937920f5906","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1719642326211940604:b27f58e3-de14-435b-a139-bf1b58e722f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1721555862580285914:1161a3a1-108b-4bed-9e48-761f6cb126ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1722505596354941417:bfa58b48-6346-4528-bb63-d163b581bb75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1723384253356900803:1635319d-a36d-46cd-9f28-573b7d480c27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1724109953626001698:36698604-5794-472e-af9d-f8f7dd192647","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725831863997268031:89acd628-faff-4d6b-9608-509d673b7bb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1726271653129105598:eb2a9e96-b33f-4902-a59b-9719df39cf96","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1726874032350298529:f45653eb-c3c4-4b4f-b23a-b2c14053f051","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734837964130377873:fbf5560d-9881-4588-845a-aff5d0bd20da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754166330394116501:4a75f573-f64e-462d-ae30-292fd5c6674f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818487400533758400:456f7cc0-4334-47a4-a8cc-df346ac1e1c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818909401543065890:f99614e0-3e12-42d8-b56f-057f150ba5b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1818980004010573955:6f9d9755-9edd-43f9-b253-51f40ded52d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819095941536010673:d152e8fa-98a0-409c-a91e-8bc8999b3f4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819154971448979801:121cced8-9fa1-41e8-b817-bd0364946a07","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819279203302343166:21cca8c5-0654-40bd-bcb1-aaf0237498fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1820069232974954849:94f30677-52d0-4872-829e-5d67ce62339f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1820802270272905460:bf407ed2-30c0-4e46-89cd-0a6fc6c3a61c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821095916952031305:1701a9ba-da61-4d26-a832-c24412fadd68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821262226545897534:5a952f40-997d-41db-8b30-bad15da01ff9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821287449944809652:0085ce07-77ea-4eff-a3b2-84c0c140476e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821451616442007742:d0bd1697-1fd8-47c9-a45a-cae587d2a1c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821502368086741010:1fef6ed9-7a32-4e51-a369-1e45b6a76f07","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821583386940768605:7511397d-dbfc-4abc-b912-87372602818f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821677672532975643:c60c1383-db22-4128-a280-9ef9acfb373a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821783114768695483:6ce55b35-c6c2-4bb7-aff4-e50213d5db26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1821803855702630738:dc6acfba-4b35-4a06-83a5-8eb33ff965ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1822114639943274870:efb466d5-bc55-4a23-935d-6542ec5fc20c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1823043583680651769:27499223-b0cc-419d-9627-5ad3ee94283e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1823162331410440616:fb8216e9-172f-472a-8a37-044d9c8e2ae9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834855707809628303:cc777883-06b6-4f5a-a886-390c630280aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834881376627077132:fb39557c-25a5-401a-8cc1-2b8029fe5af3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834940191217189016:2f66f38d-aeab-4473-b648-6fda569f2fe7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1838287211503984667:b43579c7-d88b-4020-a067-2bd1fbc5fb18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1861016108125364488:17f2b348-43e2-4e89-8be2-3733afa3ab9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865798950113935399:4170e6c0-2116-42a5-969c-76189deece39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928063317504843784:82d95203-41d0-4588-a3a6-dc617de9c7f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928318535610098164:34f40c98-48ac-49e7-b8ae-f50b2ec4ca16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1937903261274796496:bd1e2fab-1551-45c7-8e5d-bc6c11448412","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010903591234482643:7ba796b5-92ca-4cbd-a600-71e7e1c18331","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2042433489224810624:22289f31-c2cc-497b-87ff-b24cf3e71042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055340569035936028:93f365dd-b030-4001-9272-f9472e79bfb6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2078537462566080725:bac1a664-00cf-48b1-8dc3-02a19aa74af9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095722382732492898:fd597464-5e62-469d-9776-5bcebd939d63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096302953707491817:32b8da2b-49ad-4fe8-ba58-fb8c40282e6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096853509316432383:b0f1d978-c134-4457-ae52-88710b604da2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097295880512487474:fda143b1-9397-4f61-9304-ea6f21997c18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097298512069161450:01837cda-b2a7-4d0a-9284-0bfce3d4455f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097499368891072616:0b833361-6b68-48d5-b658-27c84187947f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100130855146406134:4e307893-9f53-43e7-864a-548cdf8c19ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100208126372774026:056b1764-5c43-4452-b36e-1270382a8dbb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100846184227090556:865d938b-2a47-48d6-b88d-04a91a7e2ffc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101023524240416863:d5dc1fbe-1172-49d1-bce6-f3b091d101b5","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BY4QeVzybgk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QCpknab8iR4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:TDe7DkOT7Sg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Yq4_iQLjTW4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bF8_pBcomLU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bG4Ec8o2u88","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bpE4kvjgAGo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:d_auTkqmUmQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:kI7uNtNDqok","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:m0gQQ2LL3cY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qdkcOkYpgwo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yNofh3NWLAo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":1,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":98,"x_video":0,"youtube":12},"by_evidence_role":{"commentary":116},"count":116,"evidence_window":{"end":"2026-09-18","start":"2018-10-19"},"retrieval_snapshot":"2026-10-31T12:42:14.113653Z","timeline":[{"count":1,"week":"2018-W42"},{"count":1,"week":"2019-W05"},{"count":1,"week":"2019-W23"},{"count":1,"week":"2019-W26"},{"count":1,"week":"2019-W39"},{"count":2,"week":"2019-W41"},{"count":1,"week":"2019-W45"},{"count":2,"week":"2019-W49"},{"count":1,"week":"2019-W51"},{"count":1,"week":"2020-W34"},{"count":1,"week":"2021-W34"},{"count":1,"week":"2021-W35"},{"count":2,"week":"2021-W38"},{"count":1,"week":"2022-W14"},{"count":1,"week":"2022-W16"},{"count":1,"week":"2022-W17"},{"count":1,"week":"2022-W18"},{"count":2,"week":"2022-W36"},{"count":1,"week":"2022-W47"},{"count":1,"week":"2023-W04"},{"count":2,"week":"2023-W13"},{"count":1,"week":"2023-W20"},{"count":1,"week":"2023-W30"},{"count":14,"week":"2023-W42"},{"count":9,"week":"2023-W43"},{"count":4,"week":"2023-W44"},{"count":4,"week":"2023-W45"},{"count":4,"week":"2023-W46"},{"count":1,"week":"2023-W47"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2024-W05"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W24"},{"count":7,"week":"2024-W31"},{"count":12,"week":"2024-W32"},{"count":2,"week":"2024-W33"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W47"},{"count":3,"week":"2024-W48"},{"count":1,"week":"2024-W49"},{"count":2,"week":"2025-W22"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W29"},{"count":2,"week":"2026-W36"},{"count":5,"week":"2026-W37"},{"count":4,"week":"2026-W38"}],"undated_sources":1}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: alectinib","status":"unmapped"},{"reason":"Unmapped registry intervention: vismodegib","status":"unmapped"},{"reason":"Unmapped registry intervention: ipatasertib","status":"unmapped"},{"brand_names":["Lynparza"],"label":"olaparib","slug":"olaparib"},{"brand_names":["Tarceva"],"label":"erlotinib","slug":"erlotinib"},{"brand_names":["Avastin"],"label":"bevacizumab","slug":"bevacizumab"},{"brand_names":["Zelboraf"],"label":"vemurafenib","slug":"vemurafenib"},{"brand_names":["Cotellic"],"label":"cobimetinib","slug":"cobimetinib"},{"reason":"Unmapped registry intervention: trastuzumab subcutaneous (sc)","status":"unmapped"},{"brand_names":["Perjeta"],"label":"pertuzumab","slug":"pertuzumab"},{"brand_names":["Tecentriq"],"label":"atezolizumab","slug":"atezolizumab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"reason":"Unmapped registry intervention: entrectinib","status":"unmapped"},{"reason":"Unmapped registry intervention: ivosidenib","status":"unmapped"},{"reason":"Unmapped registry intervention: pemigatinib","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Cancer of Unknown Primary Site","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"CUPISCO","aliases":["CUPISCO","A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy"],"brief_title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","collaborators":["Foundation Medicine"],"conditions":["Cancer of Unknown Primary Site"],"display_condition":"unfavourable cancer of unknown primary","display_interventions":[["alectinib"],["vismodegib"],["ipatasertib"]],"enrollment":{"count":529,"type":"ACTUAL"},"interventions":[{"name":"Alectinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Vismodegib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ipatasertib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Olaparib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Erlotinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Bevacizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Vemurafenib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cobimetinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Trastuzumab Subcutaneous (SC)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pertuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Atezolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Entrectinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ivosidenib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemigatinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT03498521","official_title":"A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2023-02-14","type":"ACTUAL"},"primary_endpoints":[{"description":"This efficacy objective was to evaluate the efficacy of MGT vs platinum chemotherapy in term of PFS in participants with CUP whose best response to 3 cycles of platinum induction chemotherapy was assessed CR, PR, or SD.","measure":"Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, until 330 PFS events were observed (approx. 4.3 years for MGT Cat 1 and 3.4 years for Chemotherapy Cat 1)."}],"registered_date":{"date":"2018-04-13","type":"ACTUAL"},"registry_last_updated":"2025-11-19","registry_url":"https://clinicaltrials.gov/study/NCT03498521","short_name":"CUPISCO","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2018-07-10","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"MX39795","type":"sponsor_study_id"},{"id":"2017-003040-20","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}